{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:46:19Z","timestamp":1781927179470,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T00:00:00Z","timestamp":1538438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41391-018-0092-3","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T14:17:41Z","timestamp":1538489861000},"page":"268-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-781X","authenticated-orcid":false,"given":"Wei Phin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Papagiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan C","family":"Latchamsetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"O\u2019Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Raff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Mena Lora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Coogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Abern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,2]]},"reference":[{"issue":"1 Suppl","key":"92_CR1","first-page":"S12","volume":"189","author":"RK Nam","year":"2013","unstructured":"Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(1 Suppl):S12\u201317. discussionS17-18","journal-title":"J Urol"},{"issue":"10 Pt 2","key":"92_CR2","doi-asserted-by":"publisher","first-page":"224s","DOI":"10.1592\/phco.21.16.224S.33997","volume":"21","author":"DT Bearden","year":"2001","unstructured":"Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy. 2001;21(10 Pt 2):224s\u2013232s.","journal-title":"Pharmacotherapy"},{"key":"92_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/520427","volume":"29","author":"JW Warren","year":"1999","unstructured":"Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745\u201358.","journal-title":"Clin Infect Dis"},{"key":"92_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.amjmed.2008.04.039","volume":"121","author":"L Johnson","year":"2008","unstructured":"Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008;121:876\u201384.","journal-title":"Am J Med"},{"key":"92_CR5","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1128\/AAC.00119-14","volume":"58","author":"G Peirano","year":"2014","unstructured":"Peirano G, Pitout JD. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother. 2014;58:2699\u2013703.","journal-title":"Antimicrob Agents Chemother"},{"key":"92_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1086\/669865","volume":"34","author":"R Banerjee","year":"2013","unstructured":"Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34:361\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"92_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cmi.2015.05.013","volume":"21","author":"MM Brigmon","year":"2015","unstructured":"Brigmon MM, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization. Clin Microbiol Infect. 2015;21:843\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"92_CR8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1086\/432940","volume":"41","author":"L Ebbing","year":"2005","unstructured":"Ebbing L, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005;41:923\u20139.","journal-title":"Clin Infect Dis"},{"key":"92_CR9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186:1830\u20134.","journal-title":"J Urol"},{"key":"92_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","volume":"198","author":"MA Liss","year":"2017","unstructured":"Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, et al. An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198:329\u201334.","journal-title":"J Urol"},{"issue":"1","key":"92_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.juro.2017.08.040","volume":"199","author":"Dimitri Papagiannopoulos","year":"2018","unstructured":"Papagiannopoulos D, Abern M, Wilson N, O\u2019Block N, Raff L, Coogan C, et al. Predictors of infectious complications after targeted prophylaxis for prostate needle biopsy. J Urol. 2017;199:155\u2013160.","journal-title":"Journal of Urology"},{"key":"92_CR12","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.juro.2008.06.052","volume":"180","author":"CF Ng","year":"2008","unstructured":"Ng CF, Chan SY. Re: The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. J Urol. 2008;179:952\u2013955. J Urol.2008;180:1570\u20131.author reply 1571.","journal-title":"J Urol."},{"key":"92_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijantimicag.2014.01.008","volume":"43","author":"MJ Roberts","year":"2014","unstructured":"Roberts MJ, Williamson DA, Hadway P, Doi SA, Gardiner RA, Paterson DL. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents. 2014;43:301\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"92_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.juro.2017.08.040","volume":"199","author":"D Papagiannopoulos","year":"2018","unstructured":"Papagiannopoulos D, Abern M, Wilson N, O\u2019Block N, Raff L, Coogan C, et al. Predictors of infectious complications after targeted prophylaxis for prostate needle biopsy. J Urol. 2018;199:155\u201360.","journal-title":"J Urol"},{"key":"92_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1128\/AAC.00665-08","volume":"53","author":"SK Morgan-Linnell","year":"2009","unstructured":"Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother. 2009;53:235\u201341.","journal-title":"Antimicrob Agents Chemother"},{"key":"92_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1128\/AAC.00123-06","volume":"50","author":"JA Karlowsky","year":"2006","unstructured":"Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006;50:2251\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"92_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","volume":"22","author":"LS Redgrave","year":"2014","unstructured":"Redgrave LS, Sutton SB, Webber MA, Piddock LJV. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22:438\u201345.","journal-title":"Trends Microbiol"},{"key":"92_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/jac\/dkq465","volume":"66","author":"WE Starre van der","year":"2011","unstructured":"van der Starre WE, van Nieuwkoop C, Paltansing S, van\u2019t Wout JW, Groeneveld GH, Becker MJ, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. 2011;66:650\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"92_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1017\/S095026881000186X","volume":"139","author":"P Rattanaumpawan","year":"2011","unstructured":"Rattanaumpawan P, Tolomeo P, Bilker WB, Fishman NO, Lautenbach E. Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients. Epidemiol Infect. 2011;139:955\u201361.","journal-title":"Epidemiol Infect"},{"key":"92_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.chemosphere.2013.02.036","volume":"138","author":"MS Rehman","year":"2015","unstructured":"Rehman MS, Rashid N, Ashfaq M, Saif A, Ahmad N, Han JI. Global risk of pharmaceutical contamination from highly populated developing countries. Chemosphere. 2015;138:1045\u201355.","journal-title":"Chemosphere"},{"issue":"1656","key":"92_CR21","doi-asserted-by":"publisher","first-page":"20130586","DOI":"10.1098\/rstb.2013.0586","volume":"369","author":"R. S. Kookana","year":"2014","unstructured":"Kookana RS, Williams M, Boxall AB, Larsson DG, Gaw S, Choi K, et al. Potential ecological footprints of active pharmaceutical ingredients: an examination of risk factors in low-, middle- and high-income countries. Philos Trans R Soc Lond B Biol Sci. 2014;369 pii: 20130586. \n                    https:\/\/doi.org\/10.1098\/rstb.2013.0586\n                    \n                  .","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"key":"92_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","volume":"14","author":"TP Van Boeckel","year":"2014","unstructured":"Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA. et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis.2014;14:742\u201350.","journal-title":"Lancet Infect Dis."},{"key":"92_CR23","unstructured":"Hoeffel EM, Rastogi S, Kim MO, Hasan S, Economics US, Administration et al. The Asian Population: 2010. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, 2012."},{"key":"92_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2967\/jnumed.115.156026","volume":"56","author":"EM Rohren","year":"2015","unstructured":"Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, et al. Determination of skeletal tumor burden on 18F-fluoride PET\/CT. J Nucl Med. 2015;56:1507\u201312.","journal-title":"J Nucl Med"},{"key":"92_CR25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/j.1464-410X.2011.10561.x","volume":"109","author":"U Patel","year":"2012","unstructured":"Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int. 2012;109:1781\u20135.","journal-title":"BJU Int"},{"key":"92_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jhin.2010.05.023","volume":"76","author":"P Rattanaumpawan","year":"2010","unstructured":"Rattanaumpawan P, Tolomeo P, Bilker WB, Fishman NO, Lautenbach E. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect. 2010;76:324\u20137.","journal-title":"J Hosp Infect"},{"key":"92_CR27","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1001\/archinte.162.21.2469","volume":"162","author":"E Lautenbach","year":"2002","unstructured":"Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial escherichia coli and klebsiella pneumoniae infections. Arch Intern Med. 2002;162:2469\u201377.","journal-title":"Arch Intern Med"},{"key":"92_CR28","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0022-5347(05)65186-5","volume":"167","author":"CB Bozeman","year":"2002","unstructured":"Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002;167:1723\u20136.","journal-title":"J Urol"},{"key":"92_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/0970-1591.127856","volume":"30","author":"MJ Speakman","year":"2014","unstructured":"Speakman MJ, Cheng X. Management of the complications of BPH\/BOO. Indian J Urol. 2014;30:208\u201313.","journal-title":"Indian J Urol"},{"key":"92_CR30","doi-asserted-by":"crossref","unstructured":"Saraswati S, Sitaraman R. Aging and the human gut microbiota\u2014from correlation to causality. Front. Microbiol. 2015;5.","DOI":"10.3389\/fmicb.2014.00764"},{"key":"92_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1742-4933-10-31","volume":"10","author":"T Magrone","year":"2013","unstructured":"Magrone T, Jirillo E. The interaction between gut microbiota and age-related changes in immune function and inflammation. Immun Ageing. 2013;10:31.","journal-title":"Immun Ageing"},{"key":"92_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/bju.12282","volume":"114","author":"L Vyas","year":"2014","unstructured":"Vyas L, Acher P, Kinsella J, Challacombe B, Chang RT, Sturch P, et al. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. BJU Int. 2014;114:32\u20137.","journal-title":"BJU Int"}],"updated-by":[{"DOI":"10.1038\/s41391-019-0133-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0092-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41391-018-0092-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:33:35Z","timestamp":1684618415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-018-0092-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1038\/s41391-018-0092-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41391-019-0133-6","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,2]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article contained an error in the name of author Alfredo Mena Lora. This has now been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}